Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions revolve around the implications of the SURPASS-CVOT trial, with users expressing their enthusiasm about the potential findings. Phrases like 'definitive evidence' and references to safety and efficacy highlight the gravity of the study. The use of terms like 'major adverse cardiovascular events' shows a serious tone, reflecting the weight of the research topic and fostering a sense of urgency in understanding its implications.
Many discussions reflect a favorable view towards the findings of the publication, indicating an overall consensus about the study's relevance.
Participants demonstrate a high level of curiosity and express eagerness to learn about the findings and their implications.
While most discussions share information about the researchers and the study, deeper engagement is noted in certain posts that mention methodologies.
There is a strong belief among participants that the study will have a significant impact on the understanding of cardiovascular safety in diabetes treatment.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics SURPASS-CVOT will provide definitive evidence as to the CV safety https://t.co/jybZ9QXN6e
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics In SURPASS-CVOT, Mounjaro achieved the primary objective by https://t.co/OasJutjTgz
https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics” Orgullosos de la gran contribución del los
@djc795 @mvaduganathan @brendonneuen @CMichaelGibson @skathire @GoggleDocs @ankeetbhatt @dranulala @ShelleyZieroth @BevTchangMD @JavedButler1 https://t.co/WvnR0U7CaN https://t.co/eqYfK1gPpE
...and here comes BROADWAY, which proves safety and efficacy of obicetrapib in patients at high CV risk by @ProfSNicholls and team! https://t.co/j6NQ9gnOOt We recently had the honour to discuss BROOKLYN and BROADWAY with @ProfSNicholls @MarkusAtHome https://t.co/j8o1yQRNhK https://t.co/MDJ73H1zrq
OPEN ACCESS: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics https://t.co/mkwZWhih7F #Cardiology https://t.co/1fntscNt6W
Prof. Dr. Stephen Nicholls presents the BROOKLYN study data on obicetrapib's effects in patients with heterozygous familial hypercholesterolemia, evaluating outcomes alongside maximum tolerated lipid-modifying…
This podcast covers vulnerable plaque, industry payments to trainees, and the trial design of tirzepatide versus dulaglutide. Insights on major adverse cardiovascular events in type 2 diabetes patients are discussed…
More from @ProfSNicholls on obicetrapid @MarkusAtHome: https://t.co/jNOFnlGUef
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics SURPASS-CVOT will provide definitive evidence as to the CV safety https://t.co/jybZ9QXN6e
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @gcfmd: @djc795 @mvaduganathan @brendonneuen @CMichaelGibson @skathire @GoggleDocs @ankeetbhatt @dranulala @ShelleyZieroth @BevTchangMD…
RT @gcfmd: @djc795 @mvaduganathan @brendonneuen @CMichaelGibson @skathire @GoggleDocs @ankeetbhatt @dranulala @ShelleyZieroth @BevTchangMD…
@djc795 @mvaduganathan @brendonneuen @CMichaelGibson @skathire @GoggleDocs @ankeetbhatt @dranulala @ShelleyZieroth @BevTchangMD @JavedButler1 https://t.co/WvnR0U7CaN https://t.co/eqYfK1gPpE
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
RT @drbennisahmed: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes an…
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics In SURPASS-CVOT, Mounjaro achieved the primary objective by https://t.co/OasJutjTgz
RT @gunnar_heine: ...and here comes BROADWAY, which proves safety and efficacy of obicetrapib in patients at high CV risk by @ProfSNicholls…
...and here comes BROADWAY, which proves safety and efficacy of obicetrapib in patients at high CV risk by @ProfSNicholls and team! https://t.co/j6NQ9gnOOt We recently had the honour to discuss BROOKLYN and BROADWAY with @ProfSNicholls @MarkusAtHome https://t.co/j8o1yQRNhK https://t.co/MDJ73H1zrq
Are you ready for our new webinar? The CETP-Inhibitor Obicetrapib in FH: BROOKLYN - Prof. Dr. Stephen Nicholls (Melbourne, Australia) youtu.be/MMdSjYmlD-8?... Guest: Prof. Stephen Nicholls Hosts: @gunnarheine.bsky.social, Prof. Custodis, Prof. Schirmer
Are you ready for our new webinar? The CETP-Inhibitor Obicetrapib in FH: BROOKLYN - Prof. Dr. Stephen Nicholls (Melbourne, Australia) https://t.co/VkyxtIhliq Guest: @ProfSNicholls Hosts: @floriancustodis @StephanSchirme1 @gunnar_heine
@KirkegaardEmil https://t.co/2gCbAryG8r
RT @AmericanHeartJ: OPEN ACCESS: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type…
RT @AmericanHeartJ: OPEN ACCESS: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type…
OPEN ACCESS: Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics https://t.co/mkwZWhih7F #Cardiology https://t.co/1fntscNt6W
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics - ScienceDirect✅☑️✅☑️ https://t.co/ouVUTI8JWK
Trend up+30: Nicholls SJ, ..., Surpass-cvot investigators (Am Heart J) __Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SUR__ https://t.co/vZBiGlINT5
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics.
Trend up+48: Nicholls SJ, ..., Surpass-cvot investigators (Am Heart J) __Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SUR__ https://t.co/vZBiGlINT5
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics. - ScienceDirect✅☑️✅☑️ https://t.co/ouVUTI8JWK
Trend up+131: Nicholls SJ, ..., Surpass-cvot investigators (Am Heart J) __Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SU__ https://t.co/vZBiGlINT5
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
RT @CristobMorales: https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participan…
https://t.co/Cb48ScLN9y “Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics” Orgullosos de la gran contribución del los